95 related articles for article (PubMed ID: 7646550)
1. Cross-resistance studies on two K562 sublines resistant to diaziridinylbenzoquinones.
Ward TH; Haran MS; Whittaker D; Watson AJ; Howard TD; Butler J
Biochem Pharmacol; 1995 Aug; 50(4):459-64. PubMed ID: 7646550
[TBL] [Abstract][Full Text] [Related]
2. Comet assay studies on the activation of two diaziridinylbenzoquinones in K562 cells.
Ward TH; Butler J; Shahbakhti H; Richards JT
Biochem Pharmacol; 1997 Apr; 53(8):1115-21. PubMed ID: 9175716
[TBL] [Abstract][Full Text] [Related]
3. The lack of correlation between toxicity and free radical formation of two diaziridinyl benzoquinones.
Lea JS; Garner HJ; Butler J; Hoey BM; Ward TH
Biochem Pharmacol; 1988 May; 37(10):2023-5. PubMed ID: 2837220
[TBL] [Abstract][Full Text] [Related]
4. Relationship between DT-diaphorase-mediated metabolism of a series of aziridinylbenzoquinones and DNA damage and cytotoxicity.
Gibson NW; Hartley JA; Butler J; Siegel D; Ross D
Mol Pharmacol; 1992 Sep; 42(3):531-6. PubMed ID: 1406604
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of diaziquone by NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase): role in diaziquone-induced DNA damage and cytotoxicity in human colon carcinoma cells.
Siegel D; Gibson NW; Preusch PC; Ross D
Cancer Res; 1990 Nov; 50(22):7293-300. PubMed ID: 2121335
[TBL] [Abstract][Full Text] [Related]
6. In vitro multidrug resistance of P388 murine leukemia selected for resistance to diaziquone.
Gutierrez PL; Wilder PJ; Biswal N
Cancer Commun; 1989; 1(3):181-90. PubMed ID: 2576972
[TBL] [Abstract][Full Text] [Related]
7. The reduction of anti-tumour diaziridinyl benzoquinones.
Butler J; Hoey BM; Lea JS
Biochim Biophys Acta; 1987 Aug; 925(2):144-9. PubMed ID: 3040109
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxicity of RH1 and related aziridinylbenzoquinones: involvement of activation by NAD(P)H:quinone oxidoreductase (NQO1) and oxidative stress.
Nemeikaite-Ceniene A; Sarlauskas J; Anusevicius Z; Nivinskas H; Cenas N
Arch Biochem Biophys; 2003 Aug; 416(1):110-8. PubMed ID: 12859987
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationships for DT-diaphorase reduction of hypoxic cell directed agents: indoloquinones and diaziridinyl benzoquinones.
Bailey SM; Suggett N; Walton MI; Workman P
Int J Radiat Oncol Biol Phys; 1992; 22(4):649-53. PubMed ID: 1544832
[TBL] [Abstract][Full Text] [Related]
10. Induction of p21 mediated by reactive oxygen species formed during the metabolism of aziridinylbenzoquinones by HCT116 cells.
Qiu X; Forman HJ; Schönthal AH; Cadenas E
J Biol Chem; 1996 Dec; 271(50):31915-21. PubMed ID: 8943236
[TBL] [Abstract][Full Text] [Related]
11. Thiol oxidation coupled to DT-diaphorase-catalysed reduction of diaziquone. Reductive and oxidative pathways of diaziquone semiquinone modulated by glutathione and superoxide dismutase.
Ordoñez ID; Cadenas E
Biochem J; 1992 Sep; 286 ( Pt 2)(Pt 2):481-90. PubMed ID: 1530580
[TBL] [Abstract][Full Text] [Related]
12. The role of NAD(P)H:quinone oxidoreductase in quinone-mediated p21 induction in human colon carcinoma cells.
Qiu XB; Cadenas E
Arch Biochem Biophys; 1997 Oct; 346(2):241-51. PubMed ID: 9343371
[TBL] [Abstract][Full Text] [Related]
13. Biochemical activation of AZQ [3,6-diaziridinyl-2,5-bis(carboethoxyamino)-1,4-benzoquinone] to its free radical species.
Gutierrez PL; Friedman RD; Bachur NR
Cancer Treat Rep; 1982 Feb; 66(2):339-42. PubMed ID: 6275990
[TBL] [Abstract][Full Text] [Related]
14. Characterization of L5178Y murine lymphoblasts resistant to quinone antitumor agents.
Begleiter A; Leith MK; McClarty G; Beenken S; Goldenberg GJ; Wright JA
Cancer Res; 1988 Apr; 48(7):1727-35. PubMed ID: 3127038
[TBL] [Abstract][Full Text] [Related]
15. Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1).
Yan C; Kepa JK; Siegel D; Stratford IJ; Ross D
Mol Pharmacol; 2008 Dec; 74(6):1657-65. PubMed ID: 18794327
[TBL] [Abstract][Full Text] [Related]
16. Activity of quinone alkylating agents in quinone-resistant cells.
Begleiter A; Leith MK
Cancer Res; 1990 May; 50(10):2872-6. PubMed ID: 1692249
[TBL] [Abstract][Full Text] [Related]
17. Reductive metabolism of diaziquone (AZQ) in the S9 fraction of MCF-7 cells. II. Enhancement of the alkylating activity of AZQ by NAD(P)H: quinone-acceptor oxidoreductase (DT-diaphorase).
Fisher GR; Donis J; Gutierrez PL
Biochem Pharmacol; 1992 Oct; 44(8):1625-35. PubMed ID: 1301071
[TBL] [Abstract][Full Text] [Related]
18. Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9.
Fitzsimmons SA; Workman P; Grever M; Paull K; Camalier R; Lewis AD
J Natl Cancer Inst; 1996 Mar; 88(5):259-69. PubMed ID: 8614004
[TBL] [Abstract][Full Text] [Related]
19. Alkylation of DNA by the new anticancer agent 3,6-diaziridinyl-2,5-bis(carboethoxyamino)-1,4-benzoquinone (AZQ).
King CL; Wong SK; Loo TL
Eur J Cancer Clin Oncol; 1984 Feb; 20(2):261-4. PubMed ID: 6538490
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial toxicity of 2,5-diaziridinyl-3,6-bis-(carboethoxyamino)-1,4-benzoquinone.
Oberc-Greenwood MA; Smith BH; Cooke C; Ellis JR; Kornblith PL; McKeever PE
J Natl Cancer Inst; 1983 Oct; 71(4):725-33. PubMed ID: 6578368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
